e-learning
resources
ERJ
2013
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension
Henkens Ivo R., Hazenoot Thomas, Boonstra Anco, Huisman Menno V., Vonk-Noordegraaf Anton
Source:
Eur Respir J 2013; 41: 872-878
Journal Issue:
April
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Henkens Ivo R., Hazenoot Thomas, Boonstra Anco, Huisman Menno V., Vonk-Noordegraaf Anton. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. Eur Respir J 2013; 41: 872-878
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options
Source: Eur Respir Rev 2009; 18: 24-28
Year: 2009
Potential pharmacological interactions between oral pulmonary arterial hypertension (PAH) therapies and new oral anticoagulants
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Year: 2012
The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study
Source: Eur Respir J 2006; 28: 138-143
Year: 2006
A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2006; 27: 578-584
Year: 2006
Type of anticoagulant therapy as a risk factor for the severity of chronic thromboembolic pulmonary hypertension
Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond
Year: 2021
Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension
Source: Eur Respir Rev 2015; 24: 272-282
Year: 2015
Chronic thromboembolic pulmonary hypertension: role of medical therapy
Source: Eur Respir J 2013; 41: 985-990
Year: 2013
Chronic thromboembolic pulmonary hypertension
Source: Eur Respir Mon 2012; 57: 108-118
Year: 2012
Adherence to guidelines of anticoagulant prescription in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an observational study
Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension
Year: 2020
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: 858-863
Year: 2005
Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2007; 30: 922-927
Year: 2007
Management of bleeding during anticoagulant therapy
Source: International Congress 2019 – Update on anticoagulant therapy: controversy and progress
Year: 2019
Direct oral anticoagulant use and thrombus detection in patients with chronic thromboembolic pulmonary hypertension referred for pulmonary thromboendarterectomy
Source: International Congress 2019 – Chronic thromboembolic pulmonary hypertension
Year: 2019
Complications of anticoagulant therapy in patients with pulmonary thromboembolism
Source: Eur Respir J 2007; 30: Suppl. 51, 604s
Year: 2007
Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013
Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
Source: Eur Respir Rev 2009; 19: 68-71
Year: 2010
Efficacy and safety of oral bosentan in patients with Down‘s syndrome and pulmonary arterial hypertension due to congenital heart disease
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH
Year: 2012
Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018
Prospects for the prevention and treatment of venous thromboembolism
Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=155
Year: 2004
Fenfluramine-like cardiovascular side-effects of benfluorex
Source: Eur Respir J 2009; 33: 684-688
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept